Details

Autor(en) / Beteiligte

• Tattevin, P.
• Dinh, A.
• Ghout, I.
• Mouton, W.
• Verdier, M.-C.
• Laurent, F.
• Lemaitre, F.
• Gatin, L.
• Saleh-Mghir, A.
• Crémieux, A.-C.

Titel

Efficacy of generic meropenem products in combination with colistin in carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis

Ist Teil von

• International journal of antimicrobial agents, 2020-11, Vol.56 (5), p.106152-106152, Article 106152

Ort / Verlag

Elsevier Ltd

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• •Carbapenemase-producing Enterobacterales (CPE) are emerging MDR bacteria responsible for invasive infections.•The optimal antibacterial regimen for CPE remains undefined.•Most experts recommend a combination of two active agents, including meropenem if the MIC is ≤8 mg/L.•Comparison of efficacy of 5 meropenem products combined with colistin in vitro and in a rabbit model of CPE osteomyelitis.•No significant difference between innovator and 4 generics in terms of bactericidal activity and selection of resistance. Guidelines for the management of carbapenemase-producing Enterobacterales (CPE) infections recommend a combination of two active agents, including meropenem if the minimum inhibitory concentration (MIC) is ≤8 mg/L. The therapeutic equivalence of meropenem generics has been challenged. We compared the bactericidal activity of meropenem innovator (AstraZeneca) and four generic products (Actavis, Kabi, Mylan and Panpharma), both in vitro and in vivo, in association with colistin. In vitro time–kill studies were performed at 4 × MIC. An experimental model of KPC-producing Klebsiella pneumoniae osteomyelitis was induced in rabbits by tibial injection of a sclerosing agent followed by 2 × 108 CFU of K. pneumoniae KPC-99YC (meropenem MIC = 4 mg/L; colistin MIC = 1 mg/L). At 14 days after inoculation, treatment for 7 days started in seven groups of ≥10 rabbits, including a control group, a colistin group, and one group for each meropenem product (i.e. the innovator and four generics), in combination with colistin. In vitro, meropenem + colistin was bactericidal with no viable bacteria after 6 h, and this effect was similar with all meropenem products. In the osteomyelitis model, there was no significant difference between meropenem generics and the innovator when combined with colistin. Colistin-resistant strains were detected after treatment with colistin + meropenem innovator (n = 3) and generics (n = 3). The efficacy of four meropenem generics did not differ from the innovator in vitro and in an experimental rabbit model of KPC-producing K. pneumoniae osteomyelitis in terms of bactericidal activity and the emergence of resistance.